awgldk
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Table
SPARQL
Graphs
1
1
Services
1
1
Assets
0
0
Insights
Schema
BETA
Class frequency
Class hierarchy
Q54316808-FF4C3C00-6EB5-480D-A789-9F95E73A24F1
Q54316808-FF4C3C00-6EB5-480D-A789-9F95E73A24F1
BestRank
Statement
http://www.wikidata.org/entity/statement/Q54316808-FF4C3C00-6EB5-480D-A789-9F95E73A24F1
Evaluation of the likelihood of a selective CHK1 inhibitor (LY2603618) to inhibit CYP2D6 with desipramine as a probe substrate in cancer patients.
P2860
Q54316808-FF4C3C00-6EB5-480D-A789-9F95E73A24F1
BestRank
Statement
http://www.wikidata.org/entity/statement/Q54316808-FF4C3C00-6EB5-480D-A789-9F95E73A24F1
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
da18f0a5ab62bddd14665812c91a6f0f5738f90f
P2860
Phase I dose-escalation study to examine the safety and tolerability of LY2603618, a checkpoint 1 kinase inhibitor, administered 1 day after pemetrexed 500 mg/m(2) every 21 days in patients with cancer